HOME Top Market Reports In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Haematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] – Forecast To 2017

In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Haematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] – Forecast To 2017

By: marketsandmarkets.com
Publishing Date: July 2013
Report Code: PH 2087

 

Enquiry Before Buying
 
purchase report
download pdf  request for customisation


Factors such as the continuous technological advancements in the field of diagnostics and an increase in healthcare awareness have made In Vitro Diagnostic testing an indispensable tool in current medical practices.

In the report, the market has been segmented on the basis of technology, product type, application, and end-users. On the basis of technology, the molecular diagnostics market is expected to grow at the highest CAGR from 2012 to 2017. The advancements in molecular techniques, increasing awareness and acceptance of personalized medicines, rise in the occurrence of chronic diseases, and the need for the diagnosis of such diseases at early stages are the key factors driving the growth of the molecular diagnostics market. On the other hand, the development of a large variety of reagents and analytical techniques, and inexpensive automated testing known as point-of-care (POC) are the factors leading to the growth in the reagents market.

The oncology diagnostics market is the fastest growing segment in in vitro diagnostic applications. Major players such as Roche Diagnostics, Siemens Healthcare, and Hologic are continuously launching new in vitro diagnostics products for the detection of cancer. In addition, point-of-care (POC) testing is also gaining popularity and is poised to grow at a high single-digit CAGR in the coming years.

Geographically, the Americas commanded the largest market share, followed by Europe. The increase in the diagnosis of chronic lifestyle diseases, genetic diseases, aging population, and rising acceptance of personalized medicine drive the in vitro diagnostic  market growth in these geographies, whereas factors such as the economic crisis and cuts in healthcare budgets hamper the growth. The BRIC (Brazil, Russia, India, and China) region exhibits various high growth opportunities for the in vitro diagnostic market. The fast-paced economy, public screening initiatives, and increase in the investment in healthcare infrastructures are the major factors that contribute to the market growth. Market players such as Thermo Fisher Scientific, Inc., QIAGEN N.V., and ARKRAY, Inc. have established new manufacturing facilities and R&D plants in China, in order to take advantage of the high growth opportunities in the country.

The deviations and the overlap of revenues between various segments of technology and applications in a number of sources was the major challenge faced while estimating the market size. This challenge was overcome by validating the data through a large number of industry experts and key opinion leaders.

From an insight perspective, this research report focuses on the various levels of analysis, namely,  industry, market shares, value chain, PESTEL analysis, and company profiles, which together comprise and augment the basic views on the competitive landscape, emerging and high growth segments of  in vitro diagnostic (molecular diagnostics & point of care testing), emerging technologies, high growth regions and countries and their respective regulatory policies, government initiative, drivers, restraints, and opportunities. Additionally, it covers the key market players and their product portfolio and the developments and strategies adopted by them to maintain and grow their market share in the near future.

The market research data, current market size, and forecast of future trends will help the key players and new entrants to make the necessary decision regarding the product offerings, geographic focus, strategic approach, R&D investment (for innovation in the products and technologies), and levels of output in order to sustain or grow successfully.

Table Of Contents 
 
1 Introduction (Page No. - 23)
  1.1 Key Take-Aways
  1.2 Report Description
  1.3 Markets Covered
  1.4 Stakeholders
  1.5 Research Methodology
      1.5.1 Market Size
      1.5.2 Market Share
      1.5.3 Key Data Points From Secondary Sources
      1.5.4 Key Data Points From Primary Sources
      1.5.5 Assumptions

2 Executive Summary (Page No. - 30)

3 Market Overview (Page No. - 33)
  3.1 Introduction
  3.2 Market Segmentation
  3.3 Market Dynamics
      3.3.1 Drivers & Restraint
            3.3.1.1 Rising Incidence Of Chronic And Infectious Diseases In Emerging Economies To Drive The Market
            3.3.1.2 Rapidly Aging Population
            3.3.1.3 Rise In Point-Of-Care (POC) Testing
            3.3.1.4 Personalized Medicine To Propel Growth
            3.3.1.5 Lack Of Budget To Restrict Growth
      3.3.2 Opportunities
            3.3.2.1 Extending Reach Of Molecular Diagnostics
            3.3.2.2 New Range Of Condition-Specific Markers And Tests With Advances In Genomics And Proteomics
      3.3.3 Challenge
            3.3.3.1 Stringent Regulatory Framework Acts As A Major Challenge
  3.4 Winning Imperatives
      3.4.1 Non-Proprietary System With Enhanced Functionalities
  3.5 Burning Issues
      3.5.1 Laboratory Automation For Increased Efficiency And Accurate Diagnosis
  3.6 Market Share Analysis
  3.7 Supply Chain Analysis
  3.8 Pestel Analysis
      3.8.1 Political
      3.8.2 Economic
      3.8.3 Socio-Cultural
      3.8.4 Technological
      3.8.5 Environmental
      3.8.6 Legal

4 By Technique (Page No. - 52)
  4.1 Introduction
      4.1.1 Clinical Chemistry
      4.1.2 Immunochemistry/Immunoassay
      4.1.3 Hematology
      4.1.4 Coagulation
      4.1.5 Microbiology
      4.1.6 Molecular Diagnostics
      4.1.7 Other Clinical Instruments

5 By Product Type (Page No. - 90)
  5.1 Introduction
  5.2 Instruments
  5.3 Reagents
  5.4 Data Management System Software/Hardware
  5.5 Services

6 By Application (Page No. - 111)
  6.1 Introduction
  6.2 Diabetes
  6.3 Infectious Diseases
  6.4 Oncology/Cancer
  6.5 Cardiology
  6.6 Nephrology
  6.7 Autoimmune Diseases
  6.8 Drug Testing
  6.9 HIV/Aids
  6.10 Others

7 By End-User (Page No. - 158)
  7.1 Introduction
  7.2 Laboratory
  7.3 Hospitals
  7.4 Academics
  7.5 Point-Of-Care Testing
  7.6 Patient Self-Testing
  7.7 Others

8 Geographic Analysis (Page No. - 164)
  8.1 Introduction
  8.2 Americas
      8.2.1 U.S.
      8.2.2 Canada
      8.2.3 Mexico
      8.2.4 Chile
      8.2.5 Rest Of Americas (ROA)
  8.3 Europe
      8.3.1 Germany
      8.3.2 France
      8.3.3 Italy
      8.3.4 Spain
      8.3.5 U.K.
      8.3.6 Rest Of Europe (ROE)
  8.4 Japan
  8.5 Bric
      8.5.1 Brazil
      8.5.2 Russia
      8.5.3 India
      8.5.4 China
  8.6 Rest Of The World (ROW)

9 Competitive Landscape (Page No. - 243)
  9.1 Introduction
  9.2 New Product Launch
  9.3 Agreements, Partnerships, Collaborations & Joint Ventures 
  9.4 Mergers And Acquisitions
  9.5 Other Developments

10 Company Profiles (Overview, Financials, Products & Services, Developments & Strategy)*  (Page No. - 282)
   10.1 Abbott Laboratories, Inc.
   10.2 Alere, Inc.
   10.3 Arkray, Inc.
   10.4 Bayer AG
   10.5 Becton, Dickinson And Company
   10.6 Biomerieux
   10.7 Bio-Rad Laboratories, Inc.
   10.8 Danaher Corporation
   10.9 Diagnostica Stago Sas
   10.10 Diasorin S.P.A.
   10.11 Hologic, Inc.
   10.12 Horiba, Ltd.
   10.13 Johnson & Johnson
   10.14 Novartis International Ag
   10.15 Qiagen N.V.
   10.16 Roche Diagnostics Limited
   10.17 Siemens Healthcare
   10.18 Sysmex Corporation
   10.19 Thermo Fisher Scientific, Inc.
   *Details On Financials, Products & Services, Developments & Strategy Might Not Be Captured In Case Of Unlisted Companies. 
 

List Of Tables (178 Tables)
 
Table 1 Global In-Vitro Diagnostic Instrument & Reagents Market Revenue, By Technique, 2012 ($Million)
Table 2 Clinical Chemistry Market, By Geography, 2010 – 2017 ($Million) 
Table 3 The Americas: Clinical Chemistry Market, By Country, 2010 – 2017 ($Million) 
Table 4 Europe: Clinical Chemistry Market, By Country, 2010 – 2017 ($Million) 
Table 5 BRIC: Clinical Chemistry Market, By Country, 2010 – 2017 ($Million) 
Table 6 Global Clinical Chemistry Market, By Instruments & Reagents, 2010 – 2017 ($Million)
Table 7 Immunochemistry Market, By Geography, 2010 – 2017 ($Million) 
Table 8 The Americas: Immunochemistry Market, By Country, 2010 – 2017 ($Million) 
Table 9 Europe: Immunochemistry Market, By Country, 2010 – 2017 ($Million) 
Table 10 BRIC: Immunochemistry Market, By Country, 2010 – 2017 ($Million) 
Table 11 Global Immunochemistry Market, By Instruments & Reagents, 2010 – 2017 ($Million)
Table 12 Hematology Market, By Geography, 2010 – 2017 ($Million)
Table 13 The Americas: Hematology Market, By Country, 2010 – 2017 ($Million) 
Table 14 Europe: Hematology Market, By Country, 2010 – 2017 ($Million) 
Table 15 BRIC: Hematology Market, By Country, 2010 – 2017 ($Million)
Table 16 Global Hematology Market, By Instruments & Reagents, 2010 – 2017 ($Million) 
Table 17 Coagulation Market, By Geography, 2010 – 2017 ($Million)
Table 18 The Americas: Coagulation Market, By Country, 2010 – 2017 ($Million) 
Table 19 Europe: Coagulation Market, By Country, 2010 – 2017 ($Million) 
Table 20 BRIC: Coagulation Market, By Country, 2010 – 2017 ($Million)
Table 21 Global Coagulation Market, By Instruments & Reagents, 2010 – 2017 ($Million) 
Table 22 Microbiology Market, By Geography, 2010 – 2017 ($Million)
Table 23 The Americas: Microbiology Market, By Country, 2010 – 2017 ($Million) 
Table 24 Europe: Microbiology Market, By Country, 2010 – 2017 ($Million) 
Table 25 BRIC: Microbiology Market, By Country, 2010 – 2017 ($Million)
Table 26 Global Microbiology Market, By Instruments & Reagents, 2010 – 2017 ($Million)
Table 27 Molecular Diagnostics Market, By Geography, 2010 – 2017 ($Million) 
Table 28 The Americas: Molecular Diagnostics Market, By Country, 2010 – 2017 ($Million)
Table 29 Europe: Molecular Diagnostics Market, By Country, 2010 – 2017 ($Million) 
Table 30 BRIC: Molecular Diagnostics Market, By Country, 2010 – 2017 ($Million) 
Table 31 Global Molecular Diagnostics Market, By Instruments & Reagents, 2010 – 2017 ($Million)
Table 32 Other In-Vitro Diagnostic Techniques Market, By Geography, 2010 – 2017 ($Million) 
Table 33 The Americas: Other In Vitro Diagnostic  Techniques Market, By Country, 2010 – 2017 ($Million) 
Table 34 Europe: Other In Vitro Diagnostic Techniques Market, By Country, 2010 – 2017 ($Million) 
Table 35 BRIC: Other In Vitro Diagnostic  Techniques Market, By Country, 2010 – 2017 ($Million) 
Table 36 Global In Vitro Diagnostic Market, By Product Type, 2010 – 2017 ($Million)
Table 37 In Vitro Diagnostic Instruments Market, By Geography, 2010 – 2017 ($Million)
Table 38 The Americas: IVD Instruments Market, By Country, 2010 – 2017 ($Million) 
Table 39 Europe: IVD Instruments Market, By Country, 2010 – 2017 ($Million) 
Table 40 BRIC: IVD Instruments Market, By Country, 2010 – 2017 ($Million) 
Table 41 In Vitro Diagnostic Reagents Market, By Geography, 2010 – 2017 ($Million)
Table 42 The Americas: IVD Reagents Market, By Country, 2010 – 2017 ($Million) 
Table 43 Europe: IVD Reagents Market, By Country, 2010 – 2017 ($Million) 
Table 44 BRIC: IVD Reagents Market, By Country, 2010 – 2017 ($Million)
Table 45 In Vitro Diagnostic Data Management System Software/Hardware Market, By Geography, 2010 – 2017 ($Million) 
Table 46 The Americas: In Vitro Diagnostic Data Management System Software/Hardware Market, By Country, 2010 – 2017 ($Million) 
Table 47 Europe: In Vitro Diagnostic Data Management System Software/Hardware Market, By Country, 2010 – 2017 ($Million)
Table 48 BRIC: In Vitro Diagnostic  Data Management System Software/Hardware Market, By Country, 2010 – 2017 ($Million)
Table 49 In Vitro Diagnostic Services Market, By Geography, 2010 – 2017 ($Million)
Table 50 The Americas: In Vitro Diagnostic Services Market, By Country, 2010 – 2017 ($Million) 
Table 51 Europe: In Vitro Diagnostic Services Market, By Country, 2010 – 2017 ($Million) 
Table 52 BRIC: In Vitro Diagnostic Services Market, By Country, 2010 – 2017 ($Million)
Table 53 Global In-Vitro Diagnostics Market, By Application, 2010 – 2017 ($Million) 
Table 54 Diabetes In Vitro Diagnostic Market, By Geography, 2010 – 2017 ($Million)
Table 55 Americas: Diabetes In Vitro Diagnostic Market, By Country, 2010 – 2017 ($Million) 
Table 56 Europe: Diabetes In Vitro Diagnostic Market, By Country, 2010 – 2017 ($Million) 
Table 57 BRIC: Diabetes In Vitro Diagnostic Market, By Country, 2010 – 2017 ($Million)
Table 58 Infectious Diseases In Vitro Diagnostics Market, By Geography, 2010 – 2017 ($Million) 
Table 59 Americas: Infectious Diseases Market, By Country, 2010 – 2017 ($Million) 
Table 60 Europe: Infectious Diseases Market, By Country, 2010 – 2017 ($Million) 
Table 61 BRIC: Infectious Diseases Market, By Country, 2010 – 2017 ($Million) 
Table 62 Oncology In Vitro Diagnostic Market, By Geography, 2010 – 2017 ($Million)
Table 63 Americas: Oncology Market, By Country, 2010 – 2017 ($Million) 
Table 64 Europe: Oncology  Market, By Country, 2010 – 2017 ($Million) 
Table 65 BRIC: Oncology Market, By Country, 2010 – 2017 ($Million)
Table 66 Cardiology In Vitro Diagnostic Market, By Geography, 2010 – 2017 ($Million)
Table 67 Americas: Cardiology Market, By Country, 2010 – 2017 ($Million) 
Table 68 Europe: Cardiology Market, By Country, 2010 – 2017 ($Million) 
Table 69 BRIC: Cardiology Market, By Country, 2010 – 2017 ($Million) 
Table 70 Nephrology In Vitro Diagnostic Market, By Geography, 2010 – 2017 ($Million)
Table 71 Americas: Nephrology Market, By Country, 2010 – 2017 ($Million) 
Table 72 Europe: Nephrology Market, By Country, 2010 – 2017 ($Million) 
Table 73 BRIC: Nephrology Market, By Country, 2010 – 2017 ($Million) 
Table 74 Autoimmune Diseases In Vitro Diagnostic Market, By Geography, 2010 – 2017 ($Million) 
Table 75 America: Autoimmune Diseases Market, By Country, 2010 – 2017 ($Million) 
Table 76 Europe: Autoimmune Diseases Market, By Country, 2010 – 2017 ($Million) 
Table 77 BRIC: Autoimmune Diseases Market, By Country, 2010 – 2017 ($Million) 
Table 78 Drug Testing In Vitro Diagnostic Market, By Geography, 2010 – 2017 ($Million)
Table 79 Americas: Drug Testing  Market, By Country, 2010 – 2017 ($Million) 
Table 80 Europe: Drug Testing In Vitro Diagnostic Market, By Country, 2010 – 2017 ($Million) 
Table 81 BRIC: Drug Testing In Vitro Diagnostic Market, By Country, 2010 – 2017 ($Million) 
Table 82 HIV/Aids In Vitro Diagnostic Market, By Geography, 2010 – 2017 ($Million)
Table 83 Americas: Hiv/Aids IVD Market, By Country, 2010 – 2017 ($Million) 
Table 84 Europe: Hiv/Aids IVD Market, By Country, 2010 – 2017 ($Million) 
Table 85 BRIC: Hiv/Aids IVD Market, By Country, 2010 – 2017 ($Million)
Table 86 Other Applications Market, By Geography, 2010 – 2017 ($Million) 
Table 87 America: Other Applications Market, By Country, 2010 – 2017 ($Million) 
Table 88 Europe: Other Applications Market, By Country, 2010 – 2017 ($Million) 
Table 89 BRIC: Other Applications Market, By Country, 2010 – 2017 ($Million) 
Table 90 Global In Vitro Diagnostics Market, By End-User, 2010 – 2017 ($Million)
Table 91 In Vitro Diagnostics Market, By Geography, 2010 – 2017 ($Million) 
Table 92 Americas: IVD Market, By Country, 2010 – 2017 ($Million)
Table 93 Americas: By Technique, 2010 – 2017 ($Million)
Table 94 Americas: By Application, 2010 – 2017 ($Million)
Table 95 Americas: By Product Type, 2010 – 2017 ($Million)
Table 96 U.S.: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 97 U.S.: By Application, 2010 – 2017 ($Million)
Table 98 U.S.: By Product Type, 2010 – 2017 ($Million)
Table 99 Canada: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 100 Canada: By Application, 2010 – 2017 ($Million)
Table 101 Canada: By Product Type, 2010 – 2017 ($Million)
Table 102 Mexico: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 103 Mexico: By Application, 2010 – 2017 ($Million)
Table 104 Mexico: By Product Type, 2010 – 2017 ($Million)
Table 105 Chile: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 106 Chile: By Application, 2010 – 2017 ($Million)
Table 107 Chile: By Product Type, 2010 – 2017 ($Million)
Table 108 ROA: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 109 ROA: By Application, 2010 – 2017 ($Million)
Table 110 ROA:  By Product Type, 2010 – 2017 ($Million)
Table 111 Europe: IVD Market, By Country, 2010 – 2017 ($Million)
Table 112 Europe: By Technique, 2010 – 2017 ($Million)
Table 113 Europe: By Application, 2010 – 2017 ($Million)
Table 114 Europe: By Product Type, 2010 – 2017 ($Million)
Table 115 Germany: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 116 Germany: By Application, 2010 – 2017 ($Million)
Table 117 Germany: By Product Type, 2010 – 2017 ($Million)
Table 118 France: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 119 France: By Application, 2010 – 2017 ($Million)
Table 120 France: By Product Type, 2010 – 2017 ($Million)
Table 121 Italy: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 122 Italy: By Application, 2010 – 2017 ($Million)
Table 123 Italy: By Product Type, 2010 – 2017 ($Million)
Table 124 Spain: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 125 Spain: By Application, 2010 – 2017 ($Million)
Table 126 Spain: By Product Type, 2010 – 2017 ($Million)
Table 127 U.K.: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 128 U.K.: By Application, 2010 – 2017 ($Million)
Table 129 U.K.: By Product Type, 2010 – 2017 ($Million)
Table 130 ROE: By Technique, 2010 – 2017 ($Million)
Table 131 ROE: By Application, 2010 – 2017 ($Million)
Table 132 ROE: By Product Type, 2010 – 2017 ($Million)
Table 133 Japan: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 134 Japan: By Application, 2010 – 2017 ($Million)
Table 135 Japan: By Product Type, 2010 – 2017 ($Million)
Table 136 BRIC: IVD Market, By Country, 2010 – 2017 ($Million)
Table 137 BRIC: By Technique, 2010 – 2017 ($Million)
Table 138 BRIC: By Application, 2010 – 2017 ($Million)
Table 139 BRIC: By Product Type, 2010 – 2017 ($Million)
Table 140 Brazil: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 141 Brazil: By Application, 2010 – 2017 ($Million)
Table 142 Brazil: By Product Type, 2010 – 2017 ($Million)
Table 143 Russia: Aging Population (Thousand)
Table 144 Russia: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 145 Russia: By Application, 2010 – 2017 ($Million)
Table 146 Russia: By Product Type, 2010 – 2017 ($Million)
Table 147 India: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 148 India: By Application, 2010 – 2017 ($Million)
Table 149 India: By Product Type, 2010 – 2017 ($Million)
Table 150 China: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 151 China: By Application, 2010 – 2017 ($Million)
Table 152 China: By Product Type, 2010 – 2017 ($Million)
Table 153 ROW: IVD Market, By Technique, 2010 – 2017 ($Million)
Table 154 ROW: By Application, 2010 – 2017 ($Million)
Table 155 ROW: By Product Type, 2010 – 2017 ($Million)
Table 156 New Product Launch, 2011 – 2013
Table 157 Agreements, Partnerships, Collaborations & Joint Ventures, 2011 – 2013
Table 158 Mergers & Acquisitions, 2011 – 2013
Table 159 Othere Developments, 2011 – 2013
Table 160 Abbott Laboratories, Inc.: Major Developments, 2011 – 2013
Table 161 Alere, Inc.: Major Developments, 2011 – 20113
Table 162 Arkray, Inc.: Major Developments, 2011 – 2013
Table 163 Bayer Ag: Major Developments, 2011 – 2013
Table 164 Becton, Dickinson And Company: Major Developments, 2011 – 2013 
Table 165 Biomerieux: Major Developments, 2011 – 2012
Table 166 Bio-Rad Laboratories, Inc.: Major Developments, 2011 – 2012
Table 167 Danaher Corporation: Major Developments, 2011 – 2013
Table 168 Diagnostica Stago Sas: Major Developments, 2011 – 2013
Table 169 Diasorin Inc.: Major Developments, 2011 – 2013
Table 170 Hologic, Inc.: Major Developments, 2011 – 2013
Table 171 Horiba, Ltd.: Major Developments, 2011 – 2012
Table 172 Johnson & Johnson: Major Developments, 2011 – 2012
Table 173 Novartis Ag: Major Developments, 2011 – 2012
Table 174 Qaigen N.V.: Major Developments, 2011 – 2013
Table 175 Roche Holdings: Major Developments, 2011 – 2013
Table 176 Siemens Healthcare: Major Developments, 2011 – 2013
Table 177 Sysmex Corporation: Major Developments, 2011 – 2013
Table 178 Thermo Fisher Scientific, Inc.: Major Developments, 2011 – 2013 
 
 
List Of Figures (50 Figures) 
 
Figure 1 Global In-Vitro Diagnostic Instrument & Reagents Market,By Technique, 2012 ($Million) 
Figure 2 Role Of In-Vitro Diagnostics In Healthcare
Figure 3 In Vitro Diagnostics Market Segmentation
Figure 4 In Vitro Diagnostics Market—Drivers & Restraints
Figure 5 Global In Vitro Diagnostics Market Share Analysis, By Key Player, 2012 
Figure 6 In Vitrp Diagnostic Market:Supply Chain Analysis
Figure 7 In Vitro Diagnostic Market: Pestel Analysis
Figure 8 Global In Vitro Diagnostics Market Segmentation, By Technique 
Figure 9 Global In Vitro Diagnostics Market, By Technique
Figure 10 Global In Vitro Diagnostics Market, By Geography, 2012
Figure 11 Key Growth Strategies, 2011 – 2013
Figure 12 Abbott Laboratories, Inc.: Total Revenue, By Segment, 2010 – 2012 ($Million) 
Figure 13 Abbott Laboratories, Inc.: Market Strategy, 2011 – 2013
Figure 14 Alere, Inc.: Total Revenue, By Segment, 2009 - 2011 ($Million)
Figure 15 Alere, Inc.: Professional Diagnostics Revenue, By Segment, 2011 – 2012 ($Million)
Figure 16 Alere, Inc.: Market Strategy, 2011 – 2013
Figure 17 Arkray, Inc.: Market Strategy, 2011 - 2012
Figure 18 Bayer AG: Total Revenue, By Segment, 2010 – 2012 ($Million)
Figure 19 Becton, Dickinson And Company: Total Revenue, By Segment, 2010 – 2012 ($Million)
Figure 20 Bd Diagnostics: Total Revenue, By Segment, 2010 – 2012 ($Million) 
Figure 21 Becton, Dickinson And Company: Market Strategy, 2011 – 2013
Figure 22 Biomerieux: Total Revenue, By Segment, 2010 – 2011 ($Million)
Figure 23 Biomerieux: Market Strategy, 2011 – 2012
Figure 24 Bio-Rad Laboratories, Inc.: Total Revenue, By Segment, 2010 – 2012 ($Million) 
Figure 25 Bio-Rad Laboratories, Inc.: Market Srategy, 2011 – 2013
Figure 26 Danaher Corporation: Total Revenue, By Segment, 2010 – 2012 ($Million) 
Figure 27 Danaher Corporation: Market Strategy, 2011 – 2013
Figure 28 Diagnostica Stago Sas: Market Strategy, 2011 – 2013
Figure 29 Diasorin S.P.A.: Total Revenue, By Technology, 2010 – 2012, ($Million) 
Figure 30 Diasorin S.P.A,: Market Strategy, 2011 – 2013
Figure 31 Hologic, Inc.: Total Revenue, By Segment, 2010 – 2012 ($Million) 
Figure 32 Hologic, Inc.: Market Srategy, 2011 – 2013
Figure 33 Horiba Ltd.: Total Revenue, By Segments, 2009 – 2011
Figure 34 Horiba, Ltd.: Market Strategy, 2011 - 2013
Figure 35 Johnson & Johnson: Total Revenue, By Segment, 2010 – 2012 ($Milllion) 
Figure 36 Johnson & Johnson: Diagnostics Franchise Revenue, 2010 – 2012 ($Million) 
Figure 37 Johnson & Johnson: Market Strategy, 2011 – 2013
Figure 38 Novartis AG: Total Revenue, By Segment, 2010 – 2012
Figure 39 Novartis AG: Market Stretegy, 2011 – 2013
Figure 40 Qiagen N.V.: Total Revenue, By Segment, 2010 – 2012 ($Million)
Figure 41 Qiagen N.V.: Market Srategy, 2011 - 2013
Figure 42 ROCHE Holdings: Diagnostics Revenue, By Segment, 2010 – 2012 ($Million) 
Figure 43 ROCHE Holdings: Diagnostics Revenue, By Geography, 2010 – 2012 ($Million) 
Figure 44 ROCHE Holdings: Market Strategy, 2011 – 2012
Figure 45 Siemens AG: Total Revenue, By Segment, 2010 – 2012 ($Million)
Figure 46 Siemens Healthcare: Market Strategy, 2011 – 2013
Figure 47 Sysmex Corporation: Diagnostics Segment Revenue, 2010 – 2012 ($Million) 
Figure 48 Sysmex Corporation: Market Strategy, 2011 – 2013
Figure 49 Thermo Fisher Scientific, Inc.: Total Revenue, By Segment, 2010 – 2012 ($Million)
Figure 50 Thermo Fisher Scientific, Inc.: Market Srategy, 2011 – 2013

The in vitro diagnostic market studied in this report has been segmented by technology, product type, application, end user, and geography. The technology market is further segmented into clinical chemistry, immunochemistry, molecular diagnostics, hematology, coagulation, microbiology, and others, of which immunochemistry accounted for the largest share with 25.8% in 2010. By product type, this market has segments like instruments, reagents, data management software/hardware, and services.

Based on applications, this market is segmented as diabetes, infectious diseases, oncology, cardiology, nephrology, auto-immune diseases, AIDS, drug testing, and others. Laboratory testing, hospital testing, academic (AMCs and university) testing, point-of-care testing, patient self-testing, and others comprise the end-user segment of the IVD market.

The global market was valued at $49.2 billion in 2012 and is expected to reach $69.1 billion by 2017, at a CAGR of 7% from 2012 to 2017. This market is primarily driven by rising incidences of chronic and infectious diseases in emerging economies, a rapidly aging population, the rise in point-of-care testing, and the rising importance of personalized medicine. However, factors such as stringent regulatory frameworks and a shortage of budget and labor are restraining the growth of the market.

In 2012, the Americas had accounted for the largest share of the global in vitro diagnostic market, followed by Europe. However, the BRIC countries represent the fastest-growing markets due to the economic growth, the rising number of chronic diseases, and an increasing awareness about the use of in vitro disgnostic tests to control the spread of diseases. Moreover, the economic slowdown, pricing pressures, and high competition in mature countries will compel companies to focus on emerging markets.

The key players are Abbott Laboratories, Inc. (U.S.), Roche Diagnostics Limited (Switzerland), Becton, Dickson and Company (U.S.), Siemens Healthcare (Germany), Diagnostica Stago SAS (France), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), ARKRAY, Inc. (Japan), Bio-Rad Laboratories, Inc. (U.S.), DiaSorin S.p.A. (Italy), Sysmex Corporation (Japan), bioMιrieux (France), HORIBA, Ltd. (Japan), and Alere, Inc. (U.S.).

GLOBAL IN-VITRO DIAGNOSTIC INSTRUMENT & REAGENTS MARKET, BY TECHNIQUE, 2012 ($MILLION)

In Vitro Diagnostic (IVD) Market

Source: Annual Reports, SEC Filings, Investor presentations, In Vitro Diagnostics Associations & Journals, WHO, European Diagnostic Manufacturers Association, American Association for Clinical Chemistry, Expert Interviews, and MnM Analysis

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports